Audio Archives

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Roche’s failure, Eisai’s success, and a live AMA

First Opinion Podcast Patrick Skerrett

Listen: The ‘First Opinion Podcast’ live from Boston: Jay Baruch returns

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

First Opinion Podcast Patrick Skerrett

Listen: Covid is not a ‘racial equity success story’

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: How the biotech revolution could come apart at the seams

First Opinion Podcast Patrick Skerrett

Listen: Will opioid settlement money actually go to opioid prevention? Here’s hoping

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

First Opinion Podcast Patrick Skerrett

Listen: Home health care is facing devastating ‘clawbacks’

First Opinion Podcast Patrick Skerrett

Listen: What makes food ‘healthy’ and why we don’t prioritize nutrition

First Opinion Podcast Patrick Skerrett

Listen: The Supreme Court set public health back 50 years. The next term could be even worse

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

First Opinion Podcast Patrick Skerrett

Listen: Wheelchair users and Medicare disagree on what’s ‘primarily medical in nature’

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

First Opinion Podcast Patrick Skerrett

Listen: How the Dobbs decision could affect how and where clinical trials are conducted

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

First Opinion Podcast Patrick Skerrett

Audio

Most Read

Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

Listen: Big changes for First Opinion

Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle

Listen: Vertex vs. insurers, Moderna’s future, & biotech’s long winter

Listen: Vas Narasimhan on the future of pharma, plus Moderna’s vaccine promise & a biotech presidential bid

Listen: The return of bird flu and the effects of pandemic fatigue

Listen: Pharma blockbusters, pandemic policy, & legal chicanery

All Coverage

Listen: Roche’s failure, Eisai’s success, and a live AMA

Listen: The ‘First Opinion Podcast’ live from Boston: Jay Baruch returns

Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy

Listen: Covid is not a ‘racial equity success story’

Listen: How the biotech revolution could come apart at the seams

Listen: Will opioid settlement money actually go to opioid prevention? Here’s hoping

Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

Listen: Home health care is facing devastating ‘clawbacks’

Listen: What makes food ‘healthy’ and why we don’t prioritize nutrition

Listen: The Supreme Court set public health back 50 years. The next term could be even worse

Listen: Nobels for science, biotech dealmaking, & a friendly FTC

Listen: Wheelchair users and Medicare disagree on what’s ‘primarily medical in nature’

Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Listen: How the Dobbs decision could affect how and where clinical trials are conducted

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Listen: Polio is back in the U.S. Two physicians offer ways to fight its spread

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day

Subscribe to STAT+ for less than $2 per day